TICKERNERD
Menu
ICUIICUIHealthcare · Medical Instruments & Supplies

ICUI Stock Forecast: ICU Medical, Inc. Price Predictions for 2026-2027

Last close, 9 Sept 2026
$161
+0.07% on the day

The 8 Wall Street analysts covering ICU Medical, Inc. hold a median 12-month price target of $193 — +19.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 8 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$4.0B
Ticker Nerd rank
96 / 100
Median analyst target
$193
Analysts covering
8
Revenue$551.7M+0.5% y/y
Operating income$60.4M
Net income$19.1M
Free cash flow$60.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.7%
1M
−12.8%
YTD
+12.8%
1Y
+23.3%
From 52W high
−14.0%
From 52W low
+41.1%
$114
$187
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ICUI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ICU Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Sept 2026
96 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
96
Value
95
Volatility
86
Issuance
79
Accruals
78
Momentum
65
Quality
63
Growth
58
Size
27

Revisions (96): Analysts have, on balance, been raising their forecasts.

Growth (58): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (27): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ICUI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ICUI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$120$140$160$180$200$220Oct 25Jan 26Apr 26Jul 26ICUIHigh $210Median $193Low $178

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $178Median $193High $210

The green dot is the last close — the median target sits +19.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
7 Aug 2026BTIGMaintainsBuy$170 → $200
7 Aug 2026NeedhamMaintainsBuy$165 → $187
7 Aug 2026Piper SandlerMaintainsOverweight$163 → $195
21 July 2026KeybancMaintainsOverweight$164 → $182
21 July 2026KeybancMaintainsOverweight—
15 June 2026BTIGInitiatesBuy—
15 June 2026BTIGInitiatesBuy$170
27 May 2026NeedhamUpgradeBuy—
27 Apr 2026KeybancMaintainsOverweight—
17 Apr 2026Piper SandlerMaintainsOverweight—
20 Feb 2026KeybancMaintainsOverweight—
20 Feb 2026Piper SandlerMaintainsOverweight—
7 Nov 2025KeybancMaintainsOverweight—
7 Nov 2025Piper SandlerMaintainsOverweight—
21 Oct 2025KeybancMaintainsOverweight—
10 Sept 2025Piper SandlerMaintainsOverweight—
15 Aug 2025Piper SandlerInitiatesOverweight—
8 Aug 2025Raymond JamesMaintainsStrong Buy—
9 May 2025Raymond JamesMaintainsStrong Buy—
21 Apr 2025KeybancMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ICUI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ICUI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 9 Sept 2026, ICU Medical, Inc. returned +23.3% against +18.5% for the S&P 500, dividends included.

ICUI vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140Oct 25Jan 26Apr 26Jul 26ICUIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ICUI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+7.1%
Analysts raising
8
Analysts cutting
0
Fundamentals

ICU Medical, Inc. (ICUI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
134.7×

Cheaper than 5% of US stocks

Price / sales
1.9×

Cheaper than 54% of US stocks

Price / book
1.9×

Cheaper than 47% of US stocks

EV / EBITDA
15.4×

Cheaper than 21% of US stocks

Growth & margins
Revenue growth (YoY)
0.5%

Higher than 28% of US stocks

Earnings growth (YoY)
−46.0%

Higher than 11% of US stocks

Gross margin
42.6%

Higher than 53% of US stocks

Operating margin
7.5%

Higher than 60% of US stocks

Net margin
1.4%

Higher than 51% of US stocks

Returns & dividend
Return on equity
1.4%

Higher than 46% of US stocks

Return on assets
1.9%

Higher than 58% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ICU Medical, Inc. (ICUI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ICU Medical, Inc. has a market value of $4.0B and an enterprise value of $5.0B.

  • Revenue in the twelve months to 30 June 2026: $2.2B. The latest quarter grew 0.5% year on year.

  • Net income over the same four quarters: $30.1M, a 1.4% net margin.

  • Diluted earnings per share, trailing twelve months: $1.18.

  • Free cash flow in the twelve months to 30 June 2026: $144.8M.

  • Shares outstanding: 25.0M.

  • Trailing P/E: 134.7×; forward P/E: 16.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • ICU Medical, Inc. employs 13,000 people — $166K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 10 Sept 2026

Data provided by Twelve Data

Peers

ICUI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
ICUIICU Medical, Inc.$4.0B
96
NVSTEnvista Holdings Corp.$4.5B
99
PLSEPulse Biosciences, Inc.$3.3B
42
MMSIMerit Medical Systems, Inc.$5.2B
92
WRBYWarby Parker, Inc.$3.0B
28
STVNStevanato Group SpA$5.5B
64
ATRCAtriCure, Inc.$2.7B
94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ICU Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ICUI news & analysis

ICU Medical to Participate in Upcoming Investor Conferences

GlobeNewsWire · 27 Aug 2026neutral

ICU Medical announced it will participate in the Wells Fargo 21st Annual Healthcare Conference, held September 9-10, 2026 at the Encore Boston Harbor in Boston, MA. Company management will attend and take part in one-on-one meetings during the event.

Why it matters — The conference participation gives investors and analysts an opportunity to engage directly with ICU Medical management, which could provide greater insight into the company.

ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings

Benzinga · 7 Aug 2026positive

ICU Medical (NASDAQ:ICUI) reported upbeat earnings for the second quarter on Thursday. Following the results, analysts boosted their forecasts for the company.

Why it matters — The upbeat second-quarter results and ensuing analyst forecast increases signal improving sentiment around ICU Medical's recent performance.

ICU Medical, Inc. (ICUI) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

ICU Medical, Inc. held its Q2 2026 earnings call, and the full transcript of the call has been published on Seeking Alpha. The item provides a record of the company's second-quarter 2026 conference call.

Why it matters — An ICUI watcher would care because the earnings call transcript contains management's commentary on the company's quarterly results and outlook.

ICU Medical Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026neutral

ICU Medical reported second-quarter revenue of $548 million, up 6% organically and 1% on a reported basis. Growth in its consumables and infusion systems businesses helped offset continued pressure in Vital Care and the effects of the IV Solutions joint venture deconsolidation.

Why it matters — The earnings call highlights organic growth in core businesses while noting ongoing headwinds in Vital Care and the deconsolidation of the IV Solutions joint venture, giving ICUI watchers a factual picture of current performance drivers.

ICU Medical (ICUI) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks Investment Research · 7 Aug 2026neutral

ICU Medical reported its earnings for the quarter ended June 2026. The article notes that its top- and bottom-line figures, along with other key metrics, can be compared against Wall Street estimates and year-ago values.

Why it matters — A ICU Medical watcher would care because this review of its Q2 metrics offers insight into how the company's quarterly performance compares with analyst expectations and prior-year results.

FAQ

Frequently asked questions about ICUI stock

What is the ICUI stock price forecast for 2026-2027?

The 8 Wall Street analysts covering ICU Medical, Inc. have a median 12-month price target of $193, with estimates ranging from $178 to $210. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ICUI stock a buy right now?

Of the 8 analysts covering ICU Medical, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ICU Medical, Inc. 96 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ICUI?

As at 8 Sept 2026, ICU Medical, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (96 of 100).

Will ICUI stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +19.6% from the last close, and Ticker Nerd's factor model ranks ICU Medical, Inc. 96 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ICUI stock forecast for 2030?

No analyst covering ICU Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ICUI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $178 to $210 over the next 12 months.

How has ICUI stock performed over the past year?

ICU Medical, Inc. returned +23.3% over the 12 months to 9 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ICU Medical, Inc. do?

ICU Medical, Inc. is a medical technology company focused on infusion therapy, vascular access, and vital care products.

What is the latest news on ICUI?

The most recent item we track (GlobeNewsWire, 27 Aug 2026): "ICU Medical to Participate in Upcoming Investor Conferences". ICU Medical announced it will participate in the Wells Fargo 21st Annual Healthcare Conference, held September 9-10, 2026 at the Encore Boston Harbor in Boston, MA. Company management will attend and take part in one-on-one meetings during the event.

Company

About ICU Medical, Inc.

ICU Medical, Inc. is a medical technology company focused on infusion therapy, vascular access, and vital care products. ICU Medical develops, manufactures, and sells a broad portfolio that includes IV pumps, needlefree connectors, IV administration sets, sterile IV solutions, closed-system transfer devices for hazardous drugs, and safety software used in hospital and alternate care settings. The company also offers hemodynamic monitoring, respiratory, anesthesia, temperature management, and other critical care products that support clinical workflows and patient safety. Its product families are designed to help healthcare providers deliver medications and fluids, reduce contamination risks, and improve efficiency across the IV continuum of care. ICU Medical serves acute care hospitals, ambulatory clinics, and home or alternate-site care environments, making it an important supplier in medical devices and hospital infrastructure.

CEO Mr. Vivek Jain · 13,000 employees · United States · https://www.icumed.com